| scholarly article | Q13442814 |
| P50 | author | Hartmut Döhner | Q66385451 |
| Konstanze Döhner | Q66385457 | ||
| P2093 | author name string | Lars Bullinger | |
| Richard F Schlenk | |||
| Dirk van den Boom | |||
| Mathias Ehrich | |||
| Matthew R Nelson | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| acute myeloid leukemia | Q264118 | ||
| DNA methylation | Q874745 | ||
| adult acute myeloid leukemia | Q53673331 | ||
| P304 | page(s) | 636-642 | |
| P577 | publication date | 2009-11-10 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Quantitative DNA methylation predicts survival in adult acute myeloid leukemia | |
| P478 | volume | 115 |
| Q37109190 | A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia |
| Q36216230 | A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies |
| Q50020673 | A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium. |
| Q37694587 | A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission |
| Q90133332 | Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications |
| Q36914091 | Acute myeloid leukaemia: optimal management and recent developments |
| Q41973082 | Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications |
| Q27851694 | Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management |
| Q35651714 | Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML |
| Q34756602 | An optimized algorithm for detecting and annotating regional differential methylation |
| Q34729972 | Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry |
| Q54357396 | Array-based DNA methylation profiling in acute myeloid leukaemia. |
| Q34318280 | Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia |
| Q36409664 | Cell of origin determines clinically relevant subtypes of MLL-rearranged AML |
| Q90160312 | Clinical developments in epigenetic-directed therapies in acute myeloid leukemia |
| Q37622957 | Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia |
| Q28253465 | DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia |
| Q92818614 | DNA methylation changes following DNA damage in prostate cancer cells |
| Q53830978 | DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. |
| Q33680945 | DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia |
| Q37797467 | DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights |
| Q42610015 | DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia |
| Q38282093 | DNMT3A: the DioNysian MonsTer of acute myeloid leukaemia. |
| Q37215179 | Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes |
| Q34183388 | Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes |
| Q92679872 | E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2 |
| Q35674189 | Epigenetic Aging Signatures Are Coherently Modified in Cancer |
| Q45057071 | Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. |
| Q64076648 | Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity |
| Q38210621 | Epigenetic deregulation in myeloid malignancies. |
| Q38736587 | Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. |
| Q38770916 | Epigenetics: A primer for clinicians |
| Q36254052 | Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients |
| Q37858877 | Gene expression profiling in MDS and AML: potential and future avenues. |
| Q44260073 | Histone methyltransferase Suv39h1 deficiency prevents Myc-induced chromosomal instability in murine myeloid leukemias |
| Q35816855 | Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia |
| Q36887700 | Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia |
| Q45070345 | ICSBP promoter methylation in myelodysplastic syndromes and acute myeloid leukaemia |
| Q55439053 | Identification of DNA methylation prognostic signature of acute myelocytic leukemia. |
| Q33908446 | Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma |
| Q35178079 | Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma |
| Q58730797 | Incorporating methylation genome information improves prediction accuracy for drug treatment responses |
| Q37226494 | Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia |
| Q55261830 | Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. |
| Q41473465 | Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia |
| Q103836619 | Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML) |
| Q48181306 | MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. |
| Q51655926 | Methylation markers in the clinical management of leukemia patients: wave of the future or just damp squib? |
| Q42362052 | MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses |
| Q47754922 | Microsphere-Based Assessment of DNA Methylation for AML Prognosis |
| Q41983993 | Microsphere-based multiplex analysis of DNA methylation in acute myeloid leukemia |
| Q50047153 | Models of Epigenetic Age Capture Patterns of DNA Methylation in Glioma Associated with Molecular Subtype, Survival, and Recurrence. |
| Q38018998 | Molecular diagnosis of leukemia |
| Q38062865 | Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations |
| Q36312989 | Multiple roles of COUP-TFII in cancer initiation and progression |
| Q36589155 | Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling |
| Q38130091 | Origins of aberrant DNA methylation in acute myeloid leukemia |
| Q38097334 | Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions |
| Q89170844 | Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association |
| Q38183943 | Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. |
| Q37817621 | Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation |
| Q90462212 | Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia |
| Q36296317 | Quantitative analyses of DAPK1 methylation in AML and MDS |
| Q35101902 | Quantitative survey of multiple CpGs from 5 genes identifies CpG methylation panel discriminating between high- and low-grade cervical intraepithelial neoplasia |
| Q42972810 | Questions regarding frontline therapy of acute myeloid leukemia |
| Q30956005 | Regulators associated with clinical outcomes revealed by DNA methylation data in breast cancer |
| Q36179524 | Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. |
| Q38296746 | Strategies for validation and testing of DNA methylation biomarkers. |
| Q36724810 | The Impact of DNA Methylation in Hematopoietic Malignancies |
| Q37731703 | The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation |
| Q21284742 | The epigenetic landscape of acute myeloid leukemia |
| Q38132064 | The evolving landscape in the therapy of acute myeloid leukemia |
| Q91752975 | The power and potential of integrated diagnostics in acute myeloid leukaemia |
| Q38198569 | The use of molecular genetics to refine prognosis in acute myeloid leukemia |
| Q35259528 | Validation of DNA methylation to predict outcome in acute myeloid leukemia by use of xMELP |
| Q36161529 | Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia |
| Q37824712 | Vorinostat in acute myeloid leukemia and myelodysplastic syndromes |
| Q34426853 | Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients |
Search more.